- Home
- ECBK vs MIST Comparison
ECBK vs MIST Comparison
Compare ECBK & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | MIST |
|---|---|---|
| Founded | 1919 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 163.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ECBK | MIST |
|---|---|---|
| Price | $16.75 | $2.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 10.5K | ★ 3.4M |
| Earning Date | 10-22-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 104.95 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $29,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.74 | ★ N/A |
| Revenue Growth | ★ 20.84 | N/A |
| 52 Week Low | $12.56 | $0.63 |
| 52 Week High | $17.75 | $2.77 |
Technical Indicators
Market Signals| Indicator | ECBK | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 70.83 |
| Support Level | $16.93 | $2.52 |
| Resistance Level | $17.55 | $2.75 |
| Average True Range (ATR) | 0.29 | 0.19 |
| MACD | -0.16 | 0.03 |
| Stochastic Oscillator | 7.56 | 86.54 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).